Teva Pharmaceutical (TEVA) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Teva Pharmaceutical (TEVA)

31.68

-0.14 (0.44%)

as of Jul 15, 2026, 6:03:36 pm Market Open.

69 watching

Investor Insights

Jul 15, 2026, 12:00 am

This summary was created by AI, based on 3 opinions in the last 12 months.

Teva Pharmaceutical (TEVA-N) is experiencing a significant turnaround under its current CEO, with a remarkable 264% increase since January 2023. The demand for GLP (glucagon-like peptides) remains strong; however, the entry of more generics into the market could lead to declining prices. While analysts highlight the potential for innovation, concerns remain about Teva's lack of innovative capabilities. The stock has shown strong momentum, breaking out over $21 in September and maintaining positive accumulation trends for the past six months. Despite not offering dividends, analysts have set a price target of $34.50 for the stock, indicating further potential growth amidst favorable market conditions for drug stocks.

Consensus

Bullish

Valuation

Undervalued

Similar

Pfizer,PFE

BUY

Largest generic pharmaceutical company globally. Having a lot of trouble getting around $50. Great company and is not expensive. Earnings will come in around $5, trading at 10X earnings. Has a terrific outlook.

BUY

Most of their drugs are generic. #1 drug is a blockbuster for MS but competition came out with a drug that had good results. Only trades at 10X earnings and has fast growth. Missed its last quarter giving an opportunity to buy at a 20% discount. With an 8 to 12 month time horizon you should do well.

DON'T BUY

Generic drugs. Has had great success over time taking drugs that are coming off patent and reformulating them. Have had a couple of hiccups in the last year or so in getting new drugs approved. Have a couple of non-generic drugs that are now being challenged by generics. Have missed a couple of estimates in a row. Prefers Perrigo (PRGO-Q).

TOP PICK

Forth quarter earnings and guidance were not what the analysts were looking for and the stock dropped. Thinks they will earn about $5/share in 2011. Significant free cash flow, double digit growth, best pipeline of any of the generic manufacturers. Very, very shareholder friendly. 25% discount to its piers.

COMMENT

Sold half his position when it was higher. Really 2 companies. Biggest part is generics. They are the biggest manufacturer globally. A lot of patented drugs will become invalid and they will grow because of it. They are also a pharmaceutical because they have a few drugs. One of them is an MS drug and a large part of their profits. It too is possibly coming up for generic competition, which has held the stock back but this is an opportunity. Probably won’t go any where for a little while. (See Top Picks.)

BUY

Loves the generic drug theme, which is a theme that will continue over the next couple of years as governments continue to cut health care coasts. Good growth.

BUY

Generic pharmaceutical company out of Israel and is the best in that market. Well run. If you have a long-term view, you should own this one.

COMMENT

Could be some major strengths in generic drugs going forward.

PAST TOP PICK

(A Top Pick Nov 26/09. Down 3.11%.) Still likes.

HOLD

Has owned for quite some time. Likes outlook for generic drug companies. They also have some of the their own drugs. There are competing drugs coming out and could be so-so for them. He sold half a couple of months ago. Likes health care in general: valuations are low and dividends are growing and there will be more demand for health-care in the US.

TOP PICK

World leader in generic drug manufacturing. Significant operations in Europe and the US. Made a couple of good acquisitions. Will benefit when other companies drugs come off patent.

BUY

One of the world's largest generic drug manufacturers. 25% global market share. Expect they can consistently grow earnings in the 10%-12% range. His target would be $55.

TOP PICK

Primarily a generic drug manufacturer. Market has overreacted with the challenge it is facing with from a competitor on one of its branded drugs. 1.5% yield.

BUY ON WEAKNESS

Leading generic drug manufacturer globally. Good growth profile. Valuations in the $40-$50 range would be decent. Growth rate is in the high mid-teens too low $20's.

DON'T BUY

Global leader with about 60% of revenues from US. Generics have recently under performed because of regulatory changes that are squeezing profitability. Generics will continue to expand market share. Acquisitions can take time for results to show in the numbers. Trading below 200 day moving average. Would prefer to see if trading above $60.

Showing 166 to 180 of 276 entries

Most Recent Experts

Colin Cieszynski

SIA Wealth Management

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Dan Rohinton

iA Global Asset Management

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Teva Pharmaceutical (TEVA)